Regenxbio inc. (RGNX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Revenues
Revenues

51,993

35,233

64,242

54,848

86,998

218,505

179,768

175,798

142,329

10,393

10,049

8,838

4,651

4,589

7,334

8,349

7,337

7,588

3,630

0

0

0

License revenue from related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

Reagent sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

261

275

212

257

232

0

0

0

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

46

-128

306

613

0

0

0

Operating Expenses
Cost of revenues

11,621

8,241

7,293

5,316

7,261

9,640

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

136,017

124,185

114,707

97,523

89,526

83,873

73,714

67,724

60,155

57,224

59,113

59,155

55,918

45,482

34,235

27,339

20,671

17,279

13,552

0

0

0

General and administrative

55,090

51,815

48,509

45,115

40,028

36,850

30,514

30,950

28,987

27,229

28,163

24,919

24,733

23,590

22,080

18,447

15,675

11,912

8,750

0

0

0

Other operating expenses

0

-

0

0

-

-42

-73

-75

-99

-116

-108

-106

-57

102

121

120

160

-31

-8

0

0

0

Foreign currency transaction losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Total operating expenses

202,785

184,231

170,466

147,901

136,829

130,405

110,716

105,330

93,267

86,278

89,805

85,953

81,662

69,929

57,706

47,400

37,732

30,725

22,967

0

0

0

Loss from operations

-150,792

-148,998

-106,224

-93,053

-49,831

88,100

69,052

70,468

49,062

-75,885

-79,756

-77,115

-77,011

-65,340

-50,372

-39,051

-30,395

-23,137

-19,337

0

0

0

Other Income (Loss)
Interest income from licensing

3,186

2,951

2,675

2,068

8,204

8,946

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income (loss)

42,378

48,559

40,843

42,534

9,206

7,070

4,778

3,259

2,646

2,716

2,541

2,452

2,384

1,938

1,835

1,336

827

346

0

0

0

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

112

0

0

0

Total other income (loss)

45,564

51,510

43,518

44,602

17,410

16,016

13,140

11,512

4,001

2,716

2,541

2,452

2,384

1,938

1,527

1,019

0

-

0

0

-

-

Loss before income taxes

-105,228

-97,488

-62,706

-48,451

-32,421

104,116

77,483

83,504

0

-

0

0

-

-

-

-

-

-

-

-

-

-

Income Tax Benefit

-

-2,755

-1,522

2,528

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss

-102,543

-94,733

-63,963

-48,581

-36,530

99,937

79,634

78,130

53,063

-73,169

-76,780

-74,228

-74,192

-62,967

-48,537

-37,715

-29,568

-22,811

-19,426

0

0

0

Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net

-521

885

1,197

1,202

804

-5

-321

-125

-331

-682

-1,406

-1,167

-847

686

1,546

0

0

-

0

-

-

-

Total other comprehensive income (loss)

-521

885

1,197

1,202

804

-5

-321

-125

-331

-682

-1,406

-1,167

-847

686

1,546

0

0

-

0

-

-

-

Comprehensive loss

-103,064

-93,848

-62,766

-47,379

-35,726

99,932

79,313

78,005

52,732

-73,851

-78,186

-75,395

-75,039

-62,281

-47,658

-37,194

-29,293

-23,530

-19,452

0

0

0

Net loss

-102,543

-94,733

-63,963

-48,581

-36,530

99,937

79,634

78,130

53,063

-73,169

-76,780

-74,228

-74,192

-62,967

-48,537

-37,715

-29,568

-22,811

-19,426

0

0

0

Net accretion and dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,747

1,873

0

0

0

Net gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

759

0

0

0

-

Net income (loss) applicable to common stockholders

-

-

-63,963

-48,581

-

99,937

79,634

78,130

53,063

-73,169

-76,780

-74,228

-74,192

-62,967

-48,537

-37,715

-32,070

-23,799

-20,540

0

0

0

Net income (loss) per share:
Basic

-

-

-0.94

-0.04

-

-0.08

-0.56

0.33

3.30

-0.49

-0.67

-0.47

-0.82

-

-

-

-

-

-

-

-

-

Diluted

-

-

-0.94

-0.04

-

-0.05

-0.56

0.30

3.04

-0.49

-0.67

-0.47

-0.82

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding:
Basic

-

-

36,813

36,669

-

36,006

33,988

32,082

31,632

31,237

30,940

30,662

26,673

-

-

-

-

-

-

-

-

-

Diluted

-

-

36,813

36,669

-

43,057

33,988

35,272

34,275

31,237

30,940

30,662

26,673

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share

-1.08

-

-

-

-0.89

-

-

-

-

-

-

-

-

-

-0.69

-0.55

-0.41

3.11

-1.52

-3.24

-0.94

-0.73

Weighted-average basic and diluted common shares outstanding

37,104

-

-

-

36,366

-

-

-

-

-

-

-

-

-

26,469

26,362

26,327

26,526

4,809

2,712

2,645

2,643

License and royalty [Member]
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

4,430

4,303

7,028

7,028

5,253

5,025

0

0

0

-

License [Member]
Costs of revenues

-

-

-

-

-

-

-

-

-

-

-

-

886

861

1,406

1,606

1,451

1,405

0

0

0

-

Other [Member]
Costs of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

98

106

128

95

98

105

0

0

0